AVITA Medical (RCEL) Q4 2025 earnings review
Stabilization Mode: Cash Burn Improves, Revenue Stalls
AVITA Medical's Q4 results reflect a company in transition. While the company successfully reduced its quarterly cash burn to $5.1 million (down from $10.1M in Q2), top-line growth has stalled due to reimbursement headwinds. Q4 revenue of $17.6M fell 4% YoY, and gross margins compressed significantly to 81.2% due to product mix. Management secured a vital debt refinancing to avoid liquidity issues, but the growth story is currently paused until the 'normalization' of reimbursement translates into actual orders in FY26.
🐂 Bull Case
The primary drag on 2025 performance—MAC reimbursement confusion—is resolving. As of January 2026, six of seven MACs have published payment rates for RECELL, removing the uncertainty that froze utilization.
Cost cuts are working. Operating expenses fell 5% YoY to $24.7M, and cash burn improved for the second consecutive quarter. The company is leaner entering FY26.
🐻 Bear Case
Gross margin dropped 640bps YoY to 81.2%. As the company sells more third-party products (Cohealyx/PermeaDerm) with ~50-60% margin profiles, the blended margin will structurally decline, pressuring the path to profitability despite revenue growth.
Commercial revenue was effectively flat to down for the entire year of 2025 (ranging $17.1M to $18.5M per quarter). FY26 guidance ($80-85M) implies ~12-19% growth, which is modest given the soft comps of 2025.
⚖️ Verdict: ⚪
Neutral. AVITA successfully navigated a liquidity squeeze through cost cuts and refinancing, but the growth thesis is in 'prove it' mode. Investors need to see the resolved reimbursement issues translate to revenue acceleration before re-rating.
Key Themes
Revenue Stagnation and Contraction
Decelerating/Negative. Revenue momentum has completely stalled. Q4 revenue of $17.6M decreased 4% YoY and grew only marginally vs Q3 ($17.1M). Management cites 'lingering impact of reimbursement headwinds,' but the lack of sequential acceleration despite the launch of new products is a concern.
Gross Margin Structurally Declining
Reversing. Gross margin fell from 87.6% in 24Q4 to 81.2% in 25Q4. This is structural, not temporary. As sales of Cohealyx (50% share) and PermeaDerm (60% share) increase, they dilute the high-margin RECELL revenue. Management admits product mix will 'continue to impact the overall gross margin percentage.'
Debt Refinancing Solves Liquidity Crunch
AVITA secured a new $60M credit facility with Perceptive Advisors (replacing OrbiMed). This is critical because the company ended Q4 with only $18.2M in cash/securities. The new facility provides more lenient covenants aligned with the current trajectory, removing the immediate risk of covenant breach that hung over the stock in 2025.
Cost Structure Rightsizing
Accelerating. Total operating expenses decreased 5% YoY to $24.7M. Sales and marketing expenses specifically dropped $2.2M due to lower compensation and commissions. This discipline helped reduce cash burn to $5.1M in Q4, the best performance in recent quarters.
Reimbursement Resolution
As of January 2026, six of seven Medicare Administrative Contractors (MACs) have published payment rates. This removes the 'key constraint on utilization' experienced in 2025. While this is positive, it is a recovery driver rather than a new growth driver—simply returning the company to a normal operating environment.
Other KPIs
Decelerating. Down from $23.3M in Q3 and $35.9M a year ago. However, the burn rate has slowed significantly ($5.1M use in Q4 vs $10.1M in Q2), and the new debt facility adds liquidity.
Stable. Identical to the net loss in 24Q4 ($11.6M). Improvement in operating expenses was offset by lower revenue and lower gross margins.
Reversing. After years of growth (e.g., +30% in 24Q4), revenue has turned negative YoY due to the MAC reimbursement issues. The company must pivot back to growth in Q1 2026 to meet debt covenants.
Guidance
Accelerating. Implies 12% to 19% growth over FY 2025 revenue of $71.6M. This assumes the resolution of reimbursement issues drives a return to volume growth.
The new credit facility requires TTM revenue of $68.5M by end of Q1 2026. Based on prior quarters, this implies the company must achieve at least $15.4M in Q1 2026 revenue to avoid default. This is a low bar compared to Q4's $17.6M, suggesting the covenant is set safely.
Key Questions
Gross Margin Floor
With the product mix shifting toward Cohealyx and PermeaDerm (50-60% margins), where do you expect the blended corporate gross margin to stabilize in FY26? Is low-80s the new normal?
Reimbursement Lag Time
Now that MAC rates are published, what is the typical lag time between publication and hospitals updating their chargemasters/ordering patterns? When should we expect the full 'normalization' benefit to hit the P&L?
Sales Force Leverage
You reduced Sales & Marketing expense by $2.2M YoY. Can the current reduced sales force support the projected 12-19% growth in FY26, or will you need to re-invest in headcount?